Inhibition of LOXL2 Enhances the Radiosensitivity of Castration-Resistant Prostate Cancer Cells Associated with the Reversal of the EMT Process

Profiling Prostate Cancer Therapeutic Resistance

(2018) Cameron Wade et al.   INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES

Crystal structure of human lysyl oxidase-like 2 (hLOXL2) in a precursor state

(2018) Xi Zhang et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Predictive value of epithelial-mesenchymal-transition (EMT) signature and PARP-1 in prostate cancer radioresistance

(2017) Timothy W. Stark et al.   PROSTATE

Functional Assays for Individual Radiosensitivity: A Critical Review

(2017) Mélanie L. Ferlazzo et al.   SEMINARS IN RADIATION ONCOLOGY

Radiosensitivity Differences Between Liver Metastases Based on Primary Histology Suggest Implications for Clinical Outcomes After Stereotactic Body Radiation Therapy

(2016) Kamran A. Ahmed et al.   INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS

Regulation of metastasis-promoting LOXL2 gene expression by antitumor microRNAs in prostate cancer

(2016) Mayuko Kato et al.   JOURNAL OF HUMAN GENETICS

10-Year Outcomes after Monitoring, Surgery, or Radiotherapy for Localized Prostate Cancer

(2016) Freddie C. Hamdy et al.   NEW ENGLAND JOURNAL OF MEDICINE

ZEB1 induces LOXL2-mediated collagen stabilization and deposition in the extracellular matrix to drive lung cancer invasion and metastasis

(2016) D H Peng et al.   ONCOGENE

Global cancer statistics, 2012

(2015) Lindsey A. Torre et al.   CA-A CANCER JOURNAL FOR CLINICIANS

E-cadherin knockdown increases β-catenin reducing colorectal cancer chemosensitivity only in three-dimensional cultures

(2015) XI LIANG et al.   INTERNATIONAL JOURNAL OF ONCOLOGY

limma powers differential expression analyses for RNA-sequencing and microarray studies

(2015) Matthew E. Ritchie et al.   NUCLEIC ACIDS RESEARCH

Lysyl oxidase-like 2 (LOXL2) from stromal fibroblasts stimulates the progression of gastric cancer

(2014) Hiroaki Kasashima et al.   CANCER LETTERS

Lysyl oxidase-like 2 (LOXL2) and E47 EMT factor: novel partners in E-cadherin repression and early metastasis colonization

(2014) G Canesin et al.   ONCOGENE

LOXL2 expression is associated with invasiveness and negatively influences survival in breast cancer patients

(2013) Sung Gwe Ahn et al.   BREAST CANCER RESEARCH AND TREATMENT

c-Met inhibitor SU11274 enhances the response of the prostate cancer cell line DU145 to ionizing radiation

(2012) Hongliang Yu et al.   BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS

E-Cadherin loss associated with EMT promotes radioresistance in human tumor cells

(2011) Jan Theys et al.   RADIOTHERAPY AND ONCOLOGY

The human lysyl oxidase-like 2 protein functions as an amine oxidase toward collagen and elastin

(2010) Young-Mi Kim et al.   MOLECULAR BIOLOGY REPORTS

The Lysyl Oxidases LOX and LOXL2 Are Necessary and Sufficient to Repress E-cadherin in Hypoxia

(2009) Ruth Schietke et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Lysyl Oxidase-Like 2 as a New Poor Prognosis Marker of Squamous Cell Carcinomas

(2008) H. Peinado et al.   CANCER RESEARCH